In the age of disruptive technologies, persistent product innovation, and fickle consumer tastes, only businesses that possess a durable competitive advantage, or wide economic moat, can stave off rivals for an extended period and sustain growth. The concept of
Wide-moat stocks that are trading meaningfully below their fair value estimates stand a better chance of outperforming the market. A measure of the credence of moat rating is borne out by the performance of the Morningstar Wide Moat Focus Index, which has returned a juicy 12.4% annually over the past 15 years, as of April 03, handily beating the 8% gains for the S&P 500 index over the same time frame.
A deep dive into the vast universe of Morningstar equity coverage turned up some formidable wide-moat names with value discount. Here’s a closer look at the following four companies that represent attractive investment opportunities.
UnitedHealth Group Inc | ||
Ticker: | UNH | |
Current yield: | 1.45% | |
Forward P/E: | 16.98 | |
Price: | US$248.78 | |
Fair value: | US$300 | |
Value: | 17% Discount | |
Data as of Apr. 05, 2019 |
The largest U.S. private health insurance provider, UnitedHealth Group (UNH) offers medical benefits to nearly 50 million members in the U.S. and globally. Thanks to its
Morningstar recently upgraded United’s moat rating to wide “driven by the cost advantages and network effects embedded within the largest private health insurance organization nationwide,” says a Morningstar equity report.
“Scale is the thread that connects its different businesses and drives the competitive advantages that allow the company to earn excess returns over time,” says Morningstar equity analyst, Jake Strole, who recently raised the stock’s fair value from US$218 to US$300, largely driven by the moat upgrade and more optimistic longer-term assumptions.
The company’s strategic investments -- acquisitions, a top health analytics product, and improving the transparency of its medical benefits -- have enabled it to remain at the leading edge of changes affecting the industry. “We expect the company to maintain its leadership position through continued product innovation while pursuing acquisition opportunities that add competencies to the enterprise,” says Strole.
Compass Minerals International Inc | ||
Ticker: | CMP | |
Current yield: | 5.08% | |
Forward P/E: | 24.04 | |
Price: | US$56.71 | |
Fair value: | US$81 | |
Value: | 30% Discount | |
Data as of Apr. 05, 2019 |
Compass Minerals (CMP) produces salt used for deicing, and sulfate of potash, a specialty fertilizer. The company’s main assets include rock salt mines in Ontario, Louisiana, and the U.K. and salt brine operations in Utah.
Compass Minerals holds an enviable portfolio of cost-advantaged assets.
These unique assets have geological advantages that are nearly impossible to replicate, affording the wide-moat Compass “a sustainable cost advantage over other producers of both salt and SOP,” says Morningstar equity analyst, Seth Goldstein, who pegs the stock’s fair value at US$81.
Proximity to ports allows Compass speed and a significant cost advantage as mines close to waterways can typically deliver deicing salt to customers at a lower cost than competitors, says Goldstein, pointing out that water transport costs “about half the cost of rail and one fifth the cost of trucking.”
Kellogg Co | ||
Ticker: | K | |
Current yield: | 3.94% | |
Forward P/E: | 14.31 | |
Price: | US$56.8 | |
Fair value: | US$78 | |
Value: | 27% Discount | |
Data as of Apr. 05, 2019 |
King of the hill in the snack market, Kellogg (K) makes and markets cereal, cookies, crackers, and other packaged foods across 180 countries.
With more than
The firm’s sustainable competitive advantage is built on
Cardinal Health Inc | ||
Ticker: | CAH | |
Current yield: | 4.01% | |
Forward P/E: | 8.73 | |
Price: | US$47.49 | |
Fair value: | US$82 | |
Value: | 42% Discount | |
Data as of Apr. 05, 2019 |
Cardinal Health (CAH) is a major distributor of pharmaceuticals and medical supplies to pharmacies and hospitals and a leading logistical partner for many branded manufacturers.
“Cardinal Health plays an important role within the healthcare market,” says a Morningstar report, noting that it is “able to turn its significant size and market share into key competitive advantages.” The firm’s entrenched position within the pharmaceutical industry should provide a solid platform for its continued success, as the use of pharmaceuticals increases over the next several years, the report says.
As the third-largest pharmaceutical distributor by revenue and the main supplier to CVS Health’s retail pharmacy operations, Cardinal possesses a wide moat. The bulk of US$400 retail pharmaceutical spending in the U.S. flows through the operations of the major three pharmaceutical distributors, including Cardinal, according to the Centers for Medicare and Medicaid Services. “This dominance drives robust and sustainable economic profits for these players,” says Morningstar sector director, Damien Conover, who puts the stock’s fair value at US$82.